ArticleVeterinarni medicina2026
Pulsed electromagnetic fields vs NSAID therapy in canine osteoarthritis: A randomised comparative pilot study.
Article in Veterinarni medicina, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are a cornerstone in the management of canine osteoarthritis (OA), despite concerns regarding their long-term safety. Among non-pharmacological alternatives, pulsed electromagnetic field (PEMF) therapy has gained attention for its potential analgesic and anti-inflammatory effects, although veterinary-specific evidence remains limited. This randomised, controlled pilot study compared the clinical efficacy of PEMF therapy versus NSAID treatment (Mavacoxib) in 16 dogs with clinically and radiographically confirmed OA. Dogs were randomly assigned to receive either a 12-session PEMF protocol over 45 days or a standard Mavacoxib regimen. Clinical evaluations included pain scores (VAS), pain on palpation, lameness severity (NRS), gait analysis (GLS and TPI), muscle circumference, and radiographic progression. Assessments were performed at baseline (T0), 30 days (T1), and 60 days (T2). PEMF therapy showed earlier improvements in pain, lameness, and muscle mass, and a favourable trend in joint mobility. No significant differences were detected in gait or radiographic parameters between groups. These preliminary findings suggest that PEMF is non-inferior to NSAIDs and highlight its potential role in multimodal OA management. Limitations include a small sample size and a short follow-up. Further studies are needed to confirm these preliminary results in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.